Warburg Pincus to invest up to $300 million in Vertice Pharma
Wednesday, November 18, 2015
Private equity firm Warburg Pincus LLC said on Tuesday it had agreed to invest up to $300 million in Vertice Pharma, a British pharmaceuticals company that will focus on buying drug makers and their products.
Vertice Pharma will be a partnership between Warburg Pincus and two pharmaceutical executives, the private equity firm said in a statement.
Among its first acquisitions, Vertice has struck a deal to buy VistaPharm, a specialized manufacturer of pain medication, Warburg Pincus said, without disclosing the details of the transaction.
Based in New York, Warburg Pincus manages over $35 billion worth of assets.
reuters.com
